Cipla Limited
CIPLA
株式のランク
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
株価
$14.63
最終同期: 2026-10-16
時価総額
$11.82B
変化（1日）
0.39%
変化（1年）
-18.37%
国
IN
取引 Cipla Limited (CIPLA)
カテゴリー
Healthcare
Cipla Limited（CIPLA）の営業利益率
October 2026 時点の営業利益率 TTM: 14.47%
Cipla Limited の最新の財務報告と株価によると、現在の営業利益率（TTM）は 14.47% です。2024 年末時点では 37.12% でした。
Cipla Limited の営業利益率の履歴（2004 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 14.47% | -62.43% |
| 2025 | 38.51% | 3.74% |
| 2024 | 37.12% | 7.41% |
| 2023 | 34.56% | -7.20% |
| 2022 | 37.24% | -3.17% |
| 2021 | 38.46% | -2.06% |
| 2020 | 39.27% | 1.87% |
| 2019 | 38.55% | -1.36% |
| 2018 | 39.08% | 1.27% |
| 2017 | 38.59% | -3.02% |
| 2016 | 39.79% | -1.66% |
| 2015 | 40.46% | 0.00% |
| 2014 | 40.46% | 77.30% |
| 2013 | 22.82% | 32.60% |
| 2012 | 17.21% | -100.50% |
| 2011 | -3,466.59% | -14,914.49% |
| 2010 | 23.40% | 24.87% |
| 2009 | 18.74% | -10.33% |
| 2008 | 20.90% | -10.99% |
| 2007 | 23.48% | -5.48% |
| 2006 | 24.84% | 3.76% |
| 2005 | 23.94% | 6.40% |
| 2004 | 22.50% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.42% |
IN
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。